

FIG. 1A




FIG. 1B





FIG. 1C






FIG. 1F

FIG. 1G




FIG. 1D

FIG. 1E






FIG. 1M




FIG. 1N




FIG. 1K





FIG. 1L






FIG. 2A




FIG. 2B




FIG. 2C





FIG. 3E




FIG. 4A




FIG. 4B





FIG. 4C

FIG. 5A






FIG. 5B

FIG. 6






FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G




FIG. 8B




FIG. 8C




FIG. 8A




FIG. 8E




FIG. 8F




FIG. 8D




FIG. 9B Untreated




FIG. 9D ANTI-ASC




FIG. 9A Sham Vehicle




FIG. 9C ENOX





FIG. 9E








FIG. 10E




FIG. 10D




FIG. 10F




FIG. 11A




FIG. 11B




FIG. 11C





FIG. 12A






FIG. 12C




FIG. 12D




FIG. 12E




FIG. 13A




FIG. 13B




FIG. 14





FIG. 15

[IC100] in Tissues






FIG. 16




FIG. 17

FIG. 18





FIG. 19








FIG. 20

ICCN 1.0H



ICCN 2.0H



ICCN 3.0H




FIG. 21

FIG. 22

ICCN 1.0H	
Isotype	IgG1
Binding to Peptide (K_D , M)	8.87E11
K_{on} (1/Ms) ¹	7.39E+06
K_{dis} (1/s) ¹	6.56E-04
Cross Reactivity	Human, mouse, rat
Functional Activity	Inhibits inflammasome pathway
ICCN 2.0H	
Isotype	IgG2 _b
Binding to Peptide (K_D , M)	3.24E11
K_{on} (1/Ms) ¹	8.59E+06
K_{dis} (1/s) ¹	2.78E-04
Cross Reactivity	Human, mouse, rat
Functional Activity	Inhibits inflammasome pathway
ICCN 3.0H	
Isotype	IgG1
Binding to Peptide (K_D , M)	5.68E11
K_{on} (1/Ms) ¹	8.91E+06
K_{dis} (1/s) ¹	5.06E-04
Cross Reactivity	Human, mouse, rat
Functional Activity	Inhibits inflammasome pathway